Kymera Therapeutics, Inc.
General ticker "KYMR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.4B (TTM average)
Kymera Therapeutics, Inc. follows the US Stock Market performance with the rate: 63.1%.
Estimated limits based on current volatility of 2.1%: low 64.78$, high 67.51$
Factors to consider:
- Total employees count: 188 (+0.5%) as of 2024
- Top business risk factors: Insufficient funding, Liquidity and credit risks, Operational and conduct risks, Intellectual property risks, Geopolitical risks
- Current price 13.1% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [25.34$, 58.57$]
- 2025-12-31 to 2026-12-31 estimated range: [19.31$, 46.76$]
Financial Metrics affecting the KYMR estimates:
- Negative: with PPE of -13.5 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.44 <= 0.33
- Positive: Shareholder equity ratio, % of 85.44 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -14.38 < Investing cash flow per share per price, % of -13.38
- Negative: negative Industry operating cash flow (median)
Short-term KYMR quotes
Long-term KYMR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $46.83MM | $78.59MM | $47.07MM |
| Operating Expenses | $208.08MM | $244.12MM | $308.71MM |
| Operating Income | $-161.26MM | $-165.53MM | $-261.63MM |
| Non-Operating Income | $6.45MM | $18.57MM | $37.78MM |
| R&D Expense | $164.25MM | $189.08MM | $240.25MM |
| Income(Loss) | $-154.81MM | $-146.96MM | $-223.86MM |
| Profit(Loss)* | $-154.81MM | $-146.96MM | $-223.86MM |
| Stockholders Equity | $490.15MM | $394.97MM | $835.62MM |
| Assets | $603.13MM | $575.76MM | $978.03MM |
| Operating Cash Flow | $-153.09MM | $-102.83MM | $-194.50MM |
| Capital expenditure | $2.84MM | $34.48MM | $12.84MM |
| Investing Cash Flow | $20.52MM | $139.89MM | $-404.08MM |
| Financing Cash Flow | $153.00MM | $4.19MM | $608.85MM |
| Earnings Per Share** | $-2.87 | $-2.52 | $-2.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.